Alnylam Pharmaceuticals (ALNY) PT Raised to $265 at Cowen

Cowen analyst Ritu Baral raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $265.00 (from $250.00) while maintaining an Outperform rating.

The analyst commented, "ALNY's APOLLO-B study of patisiran in TTR-CM met stat sig on both the primary 6MWT and secondary KCCQ, with a solid trend on composite cardiac endpoints, achieving a near best case scenario for ALNY. We believe data has a significantly positive read-through to HELIOS-B success in 2024. We think data detail at ISA, and potential further CV detail at HFSA, will further build value and confidence."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
• Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo